Dalvance, Xydalba (dalbavancin) is an unknown pharmaceutical. Dalbavancin was first approved as Dalvance on 2014-05-23. It is used to treat bacterial infections, infectious skin diseases, staphylococcal infections, and streptococcal infections in the USA. It has been approved in Europe to treat bacterial skin diseases and soft tissue infections. Dalvance's patents are valid until 2023-12-25 (FDA).
|Indication||bacterial infections, bacterial skin diseases, infectious skin diseases, soft tissue infections, staphylococcal infections, streptococcal infections|
|Drug Class||Vancomycin-related compounds|